Molecular Partners AG (XSWX:MOLN) Float Percentage Of Total Shares Outstanding : 68.57% (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Molecular Partners AG's float shares is 22.54 Mil. Molecular Partners AG's total shares outstanding is 32.87 Mil. Molecular Partners AG's float percentage of total shares outstanding is 68.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Molecular Partners AG's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Molecular Partners AG's Institutional Ownership is 11.40%.

Molecular Partners AG Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Molecular Partners AG's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	22.54	/	32.87
	=	68.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.